217 related articles for article (PubMed ID: 23221337)
1. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Chang T; Krisman K; Theobald EH; Xu J; Akutagawa J; Lauchle JO; Kogan S; Braun BS; Shannon K
J Clin Invest; 2013 Jan; 123(1):335-9. PubMed ID: 23221337
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
3. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
[TBL] [Abstract][Full Text] [Related]
4. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
[TBL] [Abstract][Full Text] [Related]
5. Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.
Staser K; Park SJ; Rhodes SD; Zeng Y; He YZ; Shew MA; Gehlhausen JR; Cerabona D; Menon K; Chen S; Sun Z; Yuan J; Ingram DA; Nalepa G; Yang FC; Clapp DW
J Clin Invest; 2013 Jan; 123(1):329-34. PubMed ID: 23221339
[TBL] [Abstract][Full Text] [Related]
6. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
[TBL] [Abstract][Full Text] [Related]
7. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.
Yin B; Delwel R; Valk PJ; Wallace MR; Loh ML; Shannon KM; Largaespada DA
Blood; 2009 Jan; 113(5):1075-85. PubMed ID: 18948576
[TBL] [Abstract][Full Text] [Related]
8. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
[TBL] [Abstract][Full Text] [Related]
9. Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Wiesner SM; Geurts JL; Diers MD; Bergerson RJ; Hasz DE; Morgan KJ; Largaespada DA
Am J Hematol; 2011 Jul; 86(7):579-85. PubMed ID: 21681782
[TBL] [Abstract][Full Text] [Related]
10. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
[TBL] [Abstract][Full Text] [Related]
11. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.
Steinemann D; Arning L; Praulich I; Stuhrmann M; Hasle H; Stary J; Schlegelberger B; Niemeyer CM; Flotho C
Haematologica; 2010 Feb; 95(2):320-3. PubMed ID: 20015894
[TBL] [Abstract][Full Text] [Related]
12. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
Sachs Z; Been RA; DeCoursin KJ; Nguyen HT; Mohd Hassan NA; Noble-Orcutt KE; Eckfeldt CE; Pomeroy EJ; Diaz-Flores E; Geurts JL; Diers MD; Hasz DE; Morgan KJ; MacMillan ML; Shannon KM; Largaespada DA; Wiesner SM
Haematologica; 2016 Oct; 101(10):1190-1199. PubMed ID: 27418650
[TBL] [Abstract][Full Text] [Related]
13. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.
Kim A; Morgan K; Hasz DE; Wiesner SM; Lauchle JO; Geurts JL; Diers MD; Le DT; Kogan SC; Parada LF; Shannon K; Largaespada DA
Blood; 2007 Feb; 109(4):1687-91. PubMed ID: 17090653
[TBL] [Abstract][Full Text] [Related]
14. Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse.
Summers MA; Vasiljevski ER; Mikulec K; Peacock L; Little DG; Schindeler A
Mol Genet Metab; 2018 Apr; 123(4):518-525. PubMed ID: 29477258
[TBL] [Abstract][Full Text] [Related]
15. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
17. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract][Full Text] [Related]
18. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
[TBL] [Abstract][Full Text] [Related]
19. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.
Miles DK; Freedman MH; Stephens K; Pallavicini M; Sievers EL; Weaver M; Grunberger T; Thompson P; Shannon KM
Blood; 1996 Dec; 88(11):4314-20. PubMed ID: 8943868
[TBL] [Abstract][Full Text] [Related]
20. Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
Ramamoorthy S; Lebrecht D; Schanze D; Schanze I; Wieland I; Andrieux G; Metzger P; Hess M; Albert MH; Borkhardt A; Bresters D; Buechner J; Catala A; De Haas V; Dworzak M; Erlacher M; Hasle H; Jahnukainen K; Locatelli F; Masetti R; Stary J; Turkiewicz D; Vinci L; Wlodarski MW; Yoshimi A; Boerries M; Niemeyer CM; Zenker M; Flotho C
Br J Haematol; 2024 Feb; 204(2):595-605. PubMed ID: 37945316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]